VEGFA and retinal vein occlusion: Retinal vein occlusion (RVO) is a major cause of visual morbidity, and macular oedema secondary to RVO is increasingly managed with repeated dexamethasone intravitreal implant (Ozurdex®) therapy, particularly in eyes with suboptimal response to anti-vascular endothelial growth factor (VEGF) agents.